Encouraging outcomes from a clinical study on the LSD-analog substance MM120, or lysergide d-tartrate, have led the Food and Drug Administration (FDA) to designate it as a “breakthrough therapy” for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback